In line with these findings, mutant K-ras activated MAPK signaling [195] through FRA1 (FOS-related antigen 1) transcriptional activity [196] to augment PD-L1 protein levels in NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.